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It also allows the provider to simulate the consequences of possible changes in the patient's prescription, overlaying all these visually in such a way as to highlight where the user may draw comfort or where the patient needs crucial medical intervention. Preliminary clinical experience with the device in a homogeneous group of type 1 patients all suffering intractable hypoglycemia is presented elsewhere.
Materials

Educational Hardware and Software
The new, educational device is called MyDiaBase+RxChecker. It is firmware that is distributed in a standard, USB flash memory drive.
2 The drive can be inserted into any USB port on any computer running any contemporary Microsoft Windows operating system. Macintosh users must have Intel OS-X and a PC emulator. The MyDiaBase portion of the device is suited for home use. The RxChecker portion of the device supports executing a prescription check by the provider at any office or clinic encounter. Together these occupy about 8 Mbytes of memory, which grow slowly with the accumulation of data entered by the patient. Flash drives of 10 Mbytes or more are fully adequate for this application.
Novel Features of MyDiaBase
For persons with diabetes, MyDiaBase is a personal diabetes registry and database. It stores patients' individual self-monitored blood glucose (SMBG) and the diabetes medical prescription (Rx). It is like a minielectronic medical record that allows users to review stored results graphically or to print all treatment outcomes as a diary or logbook.
Novel Features of RxChecker
With RxChecker, providers can improve the care of their patients by: (1) tracking body weight closely; (2) determining when any prescribed medications drift outside safe limits; (3) achieving better blood glucose control; (4) realizing safer hemoglobin A1c values; (5) using a built-in simulator to explore ±changes in their medications; (6) fostering less hypoglycemia, (7) allowing less hyperglycemia; (8) signaling when the patient should contact their doctor; (9) and clearly indicating what to talk about. All of these serve to keep the Rx in step with the patient's (changing) needs.
Impact on the Circle of Care
Together the MyDiaBase and RxChecker components help care providers track their diabetes management. The flash drive is a hardware platform that has become highly conducive to personal use. Reliability and portability with data safety and security are achieved at a relatively insignificant cost. Data in flash drives can be backed up and then restored if the device is lost.
Closing the circle of care may be facilitated when both patients and providers make use of the MyDiaBase+RxChecker technology.
Developer and Availability
The firmware was developed by a team directed by one of us (AMA). The rationale for the technology, along with its efficacy, validity, and safety, has been described elsewhere. [3] [4] [5] [6] Devices are available, and professional user training is offered. 
Installation and Personalization
Each flash drive includes all the resources with which to install the MyDiaBase+RxChecker program. Installation must be done once on each computer where the user will be running the program in the future. Once installed, each MyDiaBase+RxChecker flash drive can be personalized with the patient's demographics, the providers' demographics, and the diabetes pharmacologic Rx. These are stored internally in a database that is secured, private, and password protected in case the flash drive is lost or stolen. At any time the patient can insert their current or previous self-management data, which are then also stored in the same database. These include their self-monitored blood glucose levels, medication dosing, body weight, and, optionally, other pertinent diet, lifestyle, exercise, and stress factors. Also, at anytime the provider can execute a comprehensive eight-point check of the patient's outcomes in view of their current prescription. Additionally, using a built-in simulator, providers can explore changes in the pharmacologic prescription that may reduce the risks of hypoglycemia or lower hyperglycemia. The impact of each change on the patient's glycated hemoglobin A1c (A1C) is predicted.
Numerical Analyses
The RxChecker portion of the device supports the performance of "prescription checks." To these ends,
RxChecker: The provider gUI Sequence
Each prescription check begins with an almost empty screen on the provider's GUI that fills progressively with each step. The process starts with current body weight entry. This leads to a comment about the BMI, which for this subject is "You are both overweight and obese." Acknowledging this message leads to a graphic display of body weight over time (not shown) where the user can trigger a mathematical analysis that fits a regression line to recent body weight data. Statistical conclusions inform the user that their patient's body weight has been (1) rising, (2) stable, or (3) falling.
Next, the medical prescription is checked in order to determine if the total daily dose of each medication falls inside limits specified for each meal, for the whole day, or for both. As appropriate, either comforting or warning messages are displayed for the user to acknowledge.
Then, using previously entered SMBG data, a profile is displayed so that the provider can view their patient's currently expected glycemic ranges at each profile point. The display helps the provider visually appreciate their patient's overall glycemic control with emphasis on those profile points that risk hypoglycemia and/or hyperglycemia. Such a profile is shown in Figure 2 on the right. Medications taken at the start of the breakfast, lunch, and dinner meal periods are shown beneath the individual profiles. No medication is taken in this a body mass index (BMI) analysis is done according to accepted standards.
7 Levels of A1C are predicted from mean SMBG, as defined previously.
8 Body weight regression analysis is done as described elsewhere. Figure 1 shows an image of the patient GUI. As an electronic diary, it captures the patient's self-management data at home, including date and time, up to 12 mealrelated SMBGs per day, all medication dosing, and body weight, along with any typed comments to document diet, exercise, lifestyle, and/or stress. The diary serves to reinforce the patient's diabetes education. Glycemic profiles are formed from recent SMBG data (up to 7 antecedent days) and then used by the providers to review the safety and efficacy of their prescriptions and therapy.
The patient's interactions with the device are active. In this way, patients become more involved in their own care. This device does not passively accept SMBG readings downloaded intermittently from meters. To determine how well the daily profile meets the physician's targets, a click of the mouse pointer applies the desired ranges to the SMBG profile. As shown in Figure 3 , this GUI screen image again presents the predicted SMBG profile on the right as in Figure 2 but with the physician's target ranges applied. Also, superimposed on the upper left of Figure 3 is a comment emphasizing that six of eight profile points are outside the target ranges. Superimposed in the middle left is a comment emphasizing that one of eight profile points risks hypoglycemia. A large banner at the top to the right of Figure 3 reinforces the warning of risks of hypoglycemia. All comments as to the number of profile points outside the specified ranges and the number risking hypoglycemia are displayed for the user to acknowledge. This acknowledgment dismisses them from the screen to the database. glycemic control. An estimated A1C that is recalculated with each dosing change shows the predicted impact on overall glycemic control. As shown in Figure 4 , four such prescription changes are predicted to consolidate all profile points into the target ranges. To achieve this, the simulator suggests (1) decreasing Prandin at breakfast to reduce the risks of hypoglycemia in the after breakfast period, (2) increasing Prandin at lunch to lower the postmeal rise, and (3) increasing Prandin at dinner to lower that postmeal rise. The simulator also suggests that the prescribed metformin ER at breakfast may need to be complemented with more metformin ER at dinner. As this is an educational resource, the simulation suggests more the direction of changes than actual amounts. In any case, with these potential changes, A1C is predicted to fall favorably from 8.3 to 6.6% and to do so without risking hypoglycemia. Figure 1 but with physician's target ranges applied. Also, superimposed on the upper left is a comment emphasizing that six of eight profile points are outside the physician's target ranges, risking diabetes complications. Superimposed in the middle left is a comment emphasizing that one of eight profile points risks hypoglycemia. Note banner at the top right with a similar warning. Up-down buttons titled delta doses in the lower left are used to simulate the impact of potential medication dosing changes on the profile shown.
Finally, using the up-down buttons titled delta doses shown in the lower left of Figure 3 , the provider can simulate the impact of potential medication dosing changes on the displayed profile. In this way, simulated interventions can be explored that may help eliminate the risks of hypoglycemia and/or improve overall Figure 4 . Potential impact of prescription changes predicted by the simulator to consolidate all profile points into physician-specified, target ranges. The simulator suggests decreasing Prandin at breakfast and increasing Prandin at lunch and at dinner while also adding metformin ER at dinner. Glycated hemoglobin A1c is predicted to fall from 8.3 to 6.6% without risking hypoglycemia.
Each potential change explored in the simulation is added to the database where it appears as a text comment that can be viewed in the diary (not shown). Where appropriate, the users are encouraged to talk to each other.
Closing the Circle of Care
Prescription checks done by providers may result in improved diabetes care in general and better (safer) glycemic control in particular. Among other benefits, triggered interventions may serve to correct details of a medical prescription that is no longer applicable. Prescription checks may teach the provider the effects (on their patient's glycemic control) of simulated changes in the pharmacologic prescription. This would be a valuable extension to medical practice. Furthermore, the knowledge so gained may offer substance for discussion at the next encounter.
Closing the circle of care in this way promises to empower users of the technology, both patients and providers, thereby improving the care of persons with diabetes.
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